Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders

Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders

BackgroundThe cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be efficacious in treating numerous IL-1-mediated pathologies. Currently, three IL-1 blockers are approved, namely anakinra, canak...

Full description

Bibliographic Details
Main Authors: Dennis D. Arnold, Ayla Yalamanoglu, Onur Boyman
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
IL-1
anakinra
bermekimab
canakinumab
gevokizumab
rilonacept
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.888392/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.888392/full

Similar Items